# Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/sorafenib-plus-hepatic-arterial-infusion-chemotherapy-with-cisplatin-versus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | M. Ikeda,Satoshi Shimizu,Tosiya Sato,Manabu Morimoto,Yasushi Kojima,Yoshitaka Inaba,Atsushi Hagihara,Masatoshi Kudo,Shoji Nakamori,Shuichi Kaneko,Rie Sugimoto,T. Tahara,Takumi Ohmura,K. Yasui,Kiyoshi Sato,Hiroshi Ishii,Junji Furuse,Takuji Okusaka |
| Citations | 171 |
| DOI | 10.1093/annonc/mdw323 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://academic.oup.com/annonc/article-pdf/27/11/2090/24174101/mdw323.pdf |
| OpenAlex ID | https://openalex.org/W2512061943 |
| PMID | 27573564 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Manabu Morimoto](https://scholariq.org/researchers/manabu-morimoto/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.